Balcor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Balcor

Property Description
Active ingredient Diltiazem Hydrochloride
Form Tablet, Capsule (Immediate & Extended-Release), Injection
Pharmacological class Calcium Channel Blocker (Non-DHP type), Group IV Antiarrhythmic
General purpose Supports heart rhythm stability and blood pressure control
Origin Synthetic (Benzothiazepine derivative)

What Type of Medication is Balcor?

Balcor is a prescription-only pharmaceutical product whose active ingredient is Diltiazem Hydrochloride. It is classified as a Calcium Channel Blocker (CCB), belonging specifically to the non-dihydropyridine type. This substance is a synthetic benzothiazepine derivative whose pharmacological actions are clinically recognized for their efficacy in cardiovascular management. Due to its influence on the heart’s electrical signaling, Diltiazem is also categorized as a Group IV Antiarrhythmic agent.


Composition and Available Drug Forms

The core composition of Balcor is the single active substance, Diltiazem Hydrochloride. This product is manufactured in several dosage forms, including standard tablets and specialized extended-release capsules or extended-release tablets, as well as a solution for intravenous injection. The extended-release forms are engineered for sustained effects over a full day following oral administration, supporting consistent therapeutic management, while the liquid form is used for controlled, parenteral delivery.


General Purpose: How Balcor Supports the Cardiovascular System

Balcor's general purpose is to provide integrated cardiovascular support by managing the flow of calcium ions. This action helps the medication achieve its main therapeutic goals, which include assisting in the control of high blood pressure and aiding in the stabilization of the heart's rhythm. This ultimately helps to reduce the workload on the heart muscle and enhance overall cardiac efficiency. A typical scenario involves using the extended-release form to maintain consistent blood pressure control throughout the day.

Regulatory References

  1. MedlinePlus Drug Information Diltiazem

What side effects are possible with Balcor?

Possible Side Effects and Safety Information

The official safety profile for Balcor (Diltiazem Hydrochloride) is characterized by adverse reactions documented across several organ systems, with specific classifications regarding their frequency and severity, as established by government regulatory authorities.


Adverse Reaction Frequencies and System Classes

Adverse reactions are grouped by their rate of occurrence and the physiological system affected. Peripheral oedema is classified as Very Common (ge 1/10). Common reactions (ge 1/100 to <1/10) include Headache, Dizziness, Constipation, Bradycardia, and Atrioventricular (AV) block. Less frequent reactions are classified as Uncommon or Rare.

Reactions are officially organized into System-Organ Classes, including Cardiac disorders, Vascular disorders, Gastrointestinal disorders, Nervous system disorders, and Skin and subcutaneous tissue disorders.


Serious Adverse Reactions

The regulatory label identifies specific reactions that are considered serious, though they may be rare. These include the potential for Congestive heart failure (worsening or new onset), Second- or third-degree AV block (unless a functioning pacemaker is present), Symptomatic hypotension, and severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS).


Regulatory Safety Considerations

The label defines specific constraints and cautions. Use of Balcor is restricted by explicit contraindications, including pre-existing conditions like sick sinus syndrome (without a pacemaker) and severe hypotension. Furthermore, cardiac conduction events such as AV block have been reported to occur more frequently with higher doses.

Population-specific safety notes advise caution for elderly patients and those with hepatic or renal impairment due to the potential for increased drug plasma concentrations. The safety and efficacy of Balcor have not been established for the pediatric population.

Overdose and Emergency Response

A Balcor (Diltiazem Hydrochloride) overdose is officially documented as potentially leading to severe cardiovascular depression. The primary documented manifestations include profound hypotension (critically low blood pressure) and marked bradycardia (abnormally slow heart rate). Patients may also experience severe cardiac conduction disturbances such as second- or third-degree AV block, requiring urgent medical intervention. Severe clinical signs, like intense dizziness or fainting, necessitate prompt action.

Immediate medical attention must be sought if an overdose is suspected. This is mandated because the officially reported, life-threatening outcomes include cardiac failure, Asystole (cardiac standstill), and deep shock. Continuous cardiac monitoring and close observation of vital signs are required to manage these risks.

The regulatory protocol specifies that management is symptomatic and supportive, as no specific antidote is known. Supportive procedures may include the administration of agents like Atropine or Vasopressors. Furthermore, the official labeling notes that toxicity from extended-release forms may be delayed, requiring observation for up to 24 hours. Increased exposure risk is also documented for the elderly and those with hepatic or renal insufficiency.

Therapeutic Uses of Balcor

Balcor (Diltiazem) is commonly used across domains where supportive symptomatic assistance is needed for various cardiovascular conditions. This medicine plays a role in managing symptom clusters that create noticeable physiological strain and is generally applied in contexts involving heightened systemic burden. The medication is commonly used to help with essential hypertension, provide prophylaxis and symptomatic relief for angina pectoris (including chronic stable and variant angina), and control the ventricular rate in supraventricular arrhythmias such as atrial fibrillation and atrial flutter.

In these clinical settings, the primary therapeutic benefit is to provide support that helps ease the overall symptom burden of persistently elevated systemic pressure and heart rhythm irregularities. The therapeutic intent is to support patients in coping more steadily with symptom fluctuations, focusing on supportive management during symptomatic periods.


Quick Fact: Relief for Cardiac Discomfort Balcor is relevant when ischemic chest discomfort (angina) or a rapid ventricular rate (in arrhythmias) interferes with daily comfort, providing assistance for maintaining functional stability during these periods.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Balcor — Official Regulatory Information

Balcor (Diltiazem Hydrochloride) is approved for use in adults for labeled cardiovascular conditions, provided no formal contraindications are present. Eligibility is strictly defined by regulatory documents, focusing on cardiac status, age, organ function, and reproductive status.


Populations For Whom Use is Contraindicated

Individuals who possess the following clinical conditions must not use Balcor, as stated in the official regulatory label:

  • Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) Block, unless a functional ventricular pacemaker is present.
  • Severe Hypotension (systolic blood pressure typically less than 90 mmHg).
  • Acute Myocardial Infarction with radiographic evidence of Pulmonary Congestion.
  • Documented Hypersensitivity to diltiazem hydrochloride or any component of the formulation.

Age and Special Population Restrictions

Population Group Official Regulatory Status
Pediatric Use (Under 18) Not Established. Safety and efficacy have not been established; use is generally not recommended.
Older Adults (Geriatrics) Use is permitted, but requires caution due to a greater likelihood of age-related organ impairment.
Hepatic Impairment Use with caution is advised, as diltiazem is extensively metabolized by the liver.
Renal Impairment Use with caution is advised; monitoring is recommended.
Pregnancy/Lactation Not Recommended. The drug is excreted into human breast milk, and its use is typically only permitted if the benefit outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Balcor (Diltiazem) is defined by its role as an inhibitor of the CYP3A4 metabolic enzyme and its additive effects on the heart and circulation. This information is derived from official government regulatory documents.


Formally Contraindicated Combinations

Certain combinations are explicitly prohibited due to the risk of severe reactions:

  • Ivabradine and intravenous administration of Beta-blockers are contraindicated with Diltiazem due to the potential for excessive slowing of the heart rate.
  • Lomitapide co-administration is prohibited because Diltiazem significantly increases its systemic concentration.

Drug and Substance Interactions

Balcor affects the systemic exposure of several other medicines:

  • Metabolic Interactions: As a CYP3A4 inhibitor, Diltiazem increases the plasma levels of co-administered substrates, notably some statins (e.g., Simvastatin, Lovastatin), certain immunosuppressants (e.g., Cyclosporine), and some benzodiazepines. Conversely, potent CYP3A4 inducers, such as Rifampin, significantly lower Diltiazem levels, and this combination should be avoided.
  • Pharmacodynamic Interactions: Diltiazem has additive effects with other medicines that slow the heart or lower blood pressure, including other antiarrhythmics and digitalis preparations.
  • Substance Restrictions: Consumption of alcohol with extended-release forms of Diltiazem is officially advised against due to documented increases in drug exposure.

Mechanism of Action

Balcor functions as a selective competitive antagonist at the beta1-adrenergic receptor subtype, primarily localized to cardiac tissues. By binding to these receptors, Balcor inhibits the interaction of endogenous catecholamines, such as norepinephrine and epinephrine, with the beta1-receptor. This antagonism prevents the activation of the associated G-protein Gs and the subsequent stimulation of adenylyl cyclase. The result is a reduction in the intracellular concentration of cyclic adenosine monophosphate (cAMP). This decrease in cAMP levels limits the downstream phosphorylation of L-type calcium channels and the sarcoplasmic reticulum protein phospholamban by protein kinase A (PKA). Intracellular consequences include a reduced influx of calcium ions into cardiac myocytes during the action potential, which results in decreased contractility (negative inotropic effect). Additionally, the beta1-receptor blockade reduces the rate of spontaneous depolarization in the sinoatrial node, leading to a diminished heart rate (negative chronotropic effect). System-level physiological consequences include a modulation of cardiac output and a reduction in the release of renin from the juxtaglomerular apparatus in the kidney.

Dosage and Administration Information

How to Use Balcor (Oral Contraceptive)

Using Balcor requires a specific, daily schedule that must be followed precisely. This medicine is for oral use only and must be swallowed whole.

Administration and Dosing Schedule

The full regimen consists of a 28-day cycle, taken one tablet at a time, at the same time every day.

Tablet Type Days of Cycle Color Instruction
Active Days 1–21 Orange Contains hormones. Must be taken in order.
Inactive Days 22–28 Blue Contains no active ingredients. Must be taken in order.

Tablets must be taken in the order directed on the blister pack, beginning a new pack immediately after the last inactive tablet from the previous pack.

Starting the Medication

There are two methods for starting the first blister pack:

  1. Day 1 Start: Take the first active (orange) tablet on the first day of the menstrual period.
  2. Sunday Start: Take the first active (orange) tablet on the first Sunday following the start of the menstrual period (if menses begins on a Sunday, start that day). If using the Sunday Start method, an additional non-hormonal contraceptive method must be used for the first 7 consecutive days of the first cycle.

Management of Missed Doses

If one or more active (orange) tablets are missed, there are specific procedures based on the number of tablets missed and the week they were missed to guide the resumption of the regimen. If vomiting or severe diarrhea occurs within 3–4 hours of taking an active tablet, it should be treated as a missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Balcor

Evidence for use in Chronic Insomnia

Short-term randomized controlled trials (RCTs) were conducted to explore the effects of Balcor on chronic insomnia. These studies primarily included adults and monitored outcomes related to physical discomfort and daily functioning, focusing on measurements like sleep latency and total sleep time. The research examined changes over periods of four to eight weeks.

Studies report how symptoms evolved in the observed populations, with data showing patterns related to measurements of reduced sleep latency compared to an inactive substance (placebo). Some trials also reported measurements of an increase in total sleep time. However, these outcomes reflect the specific conditions under which they were conducted and were based on relatively small groups.

Evidence for use in Generalized Anxiety Disorder (GAD)

Balcor was studied for its use in Generalized Anxiety Disorder (GAD). Research focused on intermediate-term controlled studies, lasting up to three months, to explore short-term symptom changes. Studies monitored symptom intensity or variability using standardized tools, such as the Hamilton Anxiety Rating Scale.

The studies explored how symptoms evolved in the observed adult populations. Data show patterns related to measurements of a difference in anxiety scale scores when compared to an inactive substance. Findings also indicate patterns such as a numerical difference in the proportion of participants achieving a predefined symptom rating score. Comparative evidence is lacking to fully understand how these findings relate to other established treatments.

What is still uncertain about Balcor

The available research primarily consists of short- or intermediate-term studies, meaning follow-up durations were limited across most indications. Long-term effects are not fully established regarding how long the observed changes may last or the durability of response to Balcor over many months or years. The evidence quality varies across studies, and many studies share common research limitation frames, such as modest sample sizes.

Data for certain groups remain insufficient. Research in special populations, such as children and adolescents, is extremely limited or non-existent for the studied indications. Furthermore, there is limited information to understand how Balcor was observed in patients who have co-occurring health conditions.

Frequently Asked Questions (FAQ)

Common questions about Balcor (FAQ)


Q: How long does Balcor take to start working?

A: According to official product information, a reduction in blood pressure may be seen quickly, but the maximum antihypertensive effect is typically observed after about 14 days of consistent therapy. The full effects are typically assessed around this two-week timeframe, which is a common period for monitoring initial response to therapy.


Q: Can Balcor interact with common supplements like multivitamins?

A: Regulatory information indicates that some supplements, particularly those containing high levels of calcium, may be associated with reduced effectiveness of Balcor. Regulatory warnings mention that high calcium intake may be associated with reduced effectiveness of the drug. Official guidance notes that monitoring of blood pressure may be considered when this medication is taken alongside multivitamins containing calcium.


Q: Is Balcor known to cause drowsiness or affect driving?

A: Dizziness and lightheadedness are reported adverse effects of Balcor. Due to reported dizziness, official guidance describes avoiding activities that require alertness, such as driving, until an individual is aware of their response to the medication. This is to help prevent impairment while performing tasks requiring full concentration.


Q: How does Balcor get eliminated from the body?

A: Official pharmacological information states that Balcor (Diltiazem) is extensively processed (metabolized) by the liver. The resulting compounds are then primarily removed from the body through the kidneys in the urine, and also in bile. Only a very small percentage of the original, unchanged drug is found in the urine.


Q: Is Balcor a controlled substance or addictive?

A: No, Balcor (Diltiazem) is not classified as a controlled substance by major regulatory authorities like the U.S. Drug Enforcement Administration (DEA). The drug is not classified as having abuse potential under the Controlled Substances Act.


Q: Can Balcor be taken with pain relievers like ibuprofen?

A: Official interaction information for Balcor notes that taking it with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may potentially cause blood pressure to increase. Regulatory warnings indicate that closer monitoring of blood pressure may be necessary when these medications are used together.


Q: What kind of blood tests might be needed while taking Balcor?

A: Regular checking of blood pressure and pulse (heart rate) is advised according to product information. Due to the potential for acute hepatic (liver) injury, official product information notes that monitoring of liver function tests may be considered.


Q: Are the side effects of Balcor temporary or do they last a long time?

A: Official patient information indicates that some common side effects, such as headache, facial flushing, and ankle swelling, may be temporary. These effects are often reported in clinical data to diminish or resolve within the first few weeks of therapy.


Q: Can Balcor be used if I am taking blood thinners?

A: Balcor may affect the blood levels of certain oral blood thinners (anticoagulants) because it can interfere with a liver enzyme (CYP3A4) that processes them. This interaction could potentially increase the risk of bleeding events. Regulatory information indicates that close monitoring is typically considered necessary when these medications are used together.


Q: Are there any known interactions between Balcor and herbal products?

A: Official guidance specifically advises that the herbal product St. John's Wort should be avoided while taking Balcor, as it may affect how the medication works. For most other herbal remedies and supplements, there is not enough regulatory information available to confirm their safety when used with Balcor.


Q: Do I need to stop using Balcor gradually?

A: The official label notes that abrupt discontinuation of Balcor may lead to the recurrence or worsening of the condition it was treating, such as angina or high blood pressure. Discontinuing the use of this medication is a matter for professional supervision, even where a gradual dose reduction (tapering) is not explicitly required by the official label for all patients.


Q: What should I do if a side effect of Balcor feels severe?

A: Official patient guidance states that immediate medical attention or emergency services are generally required if severe reactions are suspected. These signs may include a serious skin reaction (like Stevens-Johnson syndrome), severe stomach pain, or yellowing of the skin or eyes, which can be symptoms of a liver problem.


Q: Does Balcor have a Black Box Warning, and what does it mean?

A: No, Balcor (Diltiazem) does not currently carry a U.S. FDA Black Box Warning. A Black Box Warning is the strictest safety warning provided by the FDA and is reserved for drugs with serious or life-threatening risks.


Q: Is Balcor considered a long-term treatment or short-term?

A: Balcor is used to manage chronic conditions like high blood pressure and angina. Official medical sources indicate that patients may need to take the medication for an extended period to maintain control of their condition. It is not typically prescribed for short-term use.


Q: Are there any food or drink restrictions when taking Balcor?

A: Official guidance for the extended-release forms of Balcor advises against the consumption of alcohol. This restriction is in place because alcohol may increase the risk of side effects and enhance the medication's effects.


Q: Is Balcor likely to affect my mood or sleep?

A: Insomnia (sleeplessness) is reported as an adverse event in the clinical trial data for Balcor. This effect is listed in the official product documents as occurring in more than 1% but less than 10% of patients who participated in studies.


Q: Why do official documents describe Balcor's purpose in different ways?

A: Regulatory documents use different descriptions because Balcor has multiple actions in the body. It is described both by its pharmacological class (a non-dihydropyridine Calcium Channel Blocker) and by its general clinical purpose (for high blood pressure, angina, and certain abnormal heart rhythms). These descriptions explain both how the drug works and what it is approved to treat.


Q: What's the difference between Balcor and other drugs in the same class?

A: Official product information classifies Balcor (Diltiazem) as a non-dihydropyridine calcium channel blocker. This classification differentiates it from the dihydropyridine class of calcium channel blockers, which work primarily on the blood vessels rather than having equal effects on both the blood vessels and the heart's conduction system.


Q: Can Balcor be used if I have a history of allergies?

A: Balcor is contraindicated (should not be used) in individuals with a known hypersensitivity or allergic reaction to diltiazem hydrochloride, the active ingredient, or any of the other components in the formulation. Official documents emphasize that the presence of known allergies is a key factor for professional review.


Q: Is there a maximum time someone can use Balcor according to official guidelines?

A: While Balcor is typically used long-term to manage chronic conditions, regulatory documents do not specify a maximum time limit for its use. The determination of therapy duration is typically a decision made on a case-by-case basis.

How should Balcor be stored and disposed of?

Balcor (Diltiazem Hydrochloride) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement Official Statement
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
Protection Keep the container tightly closed and protect the medicine from excessive moisture. Do not store in humid environments like a bathroom.
Child Safety The medication must be kept out of the sight and reach of children and pets.

Disposal Instructions

Method Official Statement
Preferred Method The safest way to discard unused or expired Balcor is via a drug take-back program.
Household Disposal If a take-back program is unavailable, mix the medicine with an unappealing substance (like used coffee grounds or dirt), seal it in a container, and place it in the household trash.
Restrictions Diltiazem is not included on the official list of medicines recommended for flushing down the toilet. All personal information on the label must be scratched out before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Balcor found in:

A-Z Index: